African swine fever vaccine will enter expanded clinical and production trials

On August 18, it was learned from the Ministry of Agriculture and Rural Affairs that the African swine fever vaccine independently developed by the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences is progressing smoothly. Based on the preliminary completion of the candidate vaccine strain laboratory and the intermediate trial stage research, the vaccine has now been completed The environmental release test is about to enter the stage of expanded clinical trials and production trials.
 
According to Bu Zhigao, director of the Harbin Veterinary Research Institute, during the environmental release test phase, the vaccine was inoculated with commercial fattening piglets and sows at 10 times and 100 times the immunization dose. Observation continued for 20 weeks. There were no clinical abnormalities such as significant temperature rise in the vaccinated pigs. Symptoms and pathological injuries. Commercial fattening piglets grow well after vaccination, and there is no vaccine virus emission and horizontal transmission. The sows were in normal estrus and breeding, and no miscarriage occurred; there was no miscarriage after the inoculation of pregnant sows, and they all gave birth normally, and no vertical transmission was observed; the growth and development of the producing piglets was good.
 
According to Tang Huajun, President of the Chinese Academy of Agricultural Sciences, with the approval of the Ministry of Agriculture and Rural Affairs, Harbin Animal Research conducted vaccine clinical trials in three bases in Heilongjiang, Henan, and Xinjiang in early April, early May and early June. 3000 commercial fattening pigs. Up to now, the immunized pigs are growing in good condition and have no obvious clinical adverse reactions; the immunized pigs have no obvious pathological changes, no vaccine poison emissions, and no horizontal transmission; the immunized pigs are challenged with strong toxins in high-level biosafety laboratories. The immune protection rate of different doses of vaccination group was above 80%.
 
In the next step, the Chinese Academy of Agricultural Sciences will continue to accelerate the production of vaccine trials and research in accordance with the work deployment of the Ministry of Agriculture and Rural Affairs, further expand the scope of clinical trials in Heilongjiang and other places, strive to complete relevant trials as soon as possible, and enter the safety certificate declaration and vaccine registration in accordance with legal procedures Process.